StockTipsArenaBeta

BUY Aurobindo Pharma — Swati Hotkar, Nirmal Bang Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

bySwati Hotkar, Nirmal Bang SecuritiesHorizon: 1–3 months1 Apr 2026via NDTV Profit

Entry₹1,339.6Inferred
Target₹1,600
Total upside +19.44% (call closed)
Stop lossNot given
At expiry₹1,552.61 Jul 2026, 3:30 pm
Expired+15.90%
Follow Swati Hotkar for new calls(50% target hit, 18 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 43 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:33 pm IST
10 supporting4 neutral0 opposing
Supports the BUY call (10)

Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma, has completed the acquisition of Lannett.

NSE · Acquisition·30 Jun · yesterday

(opens in new tab)

Aurobindo Pharma Ltd has announced the completion of an acquisition.

BSE · Company Update·25 Jun · 5d ago

(opens in new tab)

Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm

NSE · Acquisition·25 Jun · 5d ago

(opens in new tab)

3 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·25 Jun · 6d ago

Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.

NSE · Press Release·22 Jun · 1w ago

(opens in new tab)
Neutral / worth noting (4)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Swati Hotkar, Nirmal Bang Securities

Every call and its outcome